CABACabaletta Bio, Inc.

Healthcare
$1.94-16% 1Y

The financials

Cabaletta Bio, Inc. by the numbers

The next results filing is expected around Nov 9, 2026, the same week as a year ago.

Cabaletta Bio, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$52M−$46Mn/a
Net income−$51M−$45Mn/a
Diluted EPS−$0.34−$0.73n/a

Biotechnology

Ranks #138 of 196 by RyuScore

Compare peers
CCCC+0.53%
C4 Therapeutics, Inc.
AGEN-0.53%
AGENUS INC
PRLD+1.6%
Prelude Therapeutics Inc
SRZN+12%
Surrozen, Inc./DE
ARTV-2.9%
Artiva Biotherapeutics, Inc.
RLMD-2.9%
RELMADA THERAPEUTICS, INC.